Primary Whole-gland Ablation for the Treatment of Clinically Localized Prostate Cancer: A Focal Therapy Society Best Practice Statement
Sriram Deivasigamani(Duke University Hospital), Ali Kasraeian(University of Florida), Ardalan E. Ahmad(Office of Education), Hashim U. Ahmed(National Health Service), Herbert Lepor(New York University), Laurence Klotz(Sunnybrook Health Science Centre), E. David Crawford(Virginia Commonwealth University), Craig Rogers(Norfolk and Norwich University Hospitals NHS Foundation Trust), Jochen Walz(Institut Paoli-Calmettes), Katsuto Shinohara(University of California, San Francisco), Giancarlo Marra(Royal Free London NHS Foundation Trust), Rafael Salas(Instituto Venezolano de Investigaciones Científicas), Zoe Michael(Duke Medical Center), Kae Jack Tay(National University of Singapore), James Wysock(New York University), Peter A. Pinto(National Institutes of Health), John F. Feller(CS Diagnostics), Jurgen J. Fütterer(Radboud University Nijmegen), Veeru Kasivisvanathan(University College London Hospitals NHS Foundation Trust), Joseph L. Chin(Western University), Inderbir S. Gill(University of Southern California), Massimo Valério(University Hospital of Geneva), Arnauld Villers(Université de Lille), Ezequiel Becher(Universidad de Buenos Aires), Eric S. Adams(Duke Medical Center), Peter Ka‐Fung Chiu(Chinese University of Hong Kong), John F. Ward(The University of Texas MD Anderson Cancer Center), Soroush Rais‐Bahrami(University of Alabama at Birmingham), Ardeshir R. Rastinehad(Royal Free London NHS Foundation Trust), Petr Macek(Institute Mutualiste Montsouris), Denis Séguier(Duke Medical Center), Andre Abreu(University of Southern California), Samir S. Taneja(NYU Langone Health), Derek J. Lomas(Mayo Clinic in Arizona), Eduard Baco(Oslo University Hospital), Wei Phin Tan(Wuhan University), Boris Hadaschik(Essen University Hospital), Sébastien Crouzet(Université de Lyon), Praveen Kumar(Post Graduate Institute of Medical Education and Research), Nathan Lawrentschuk(Peter MacCallum Cancer Centre), Jean de la Rosette(Radboud University Nijmegen), Mark Emberton(University College London), Antonio Finelli(University Health Network), Kian Tai Chong, Gustavo Cardoso Guimarães(Beneficência Portuguesa de São Paulo), Aaron E. Katz(Columbia University), Cary N. Robertson(Cancer Institute (WIA)), Srinath Kotamarti(Cancer Institute (WIA)), Nikos I. Mertziotis(Metropolitan Hospital), Phillip D. Stricker(Prostate Cancer Foundation of Australia)
Cited by 42
Related Papers
Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study
|The Lancet|2017|3.2k
Noninvasive Detection of Clinically Occult Lymph-Node Metastases in Prostate Cancer
|New England Journal of Medicine|2003|2k
The Clinical Research Office of the Endourological Society Percutaneous Nephrolithotomy Global Study: Indications, Complications, and Outcomes in 5803 Patients
|Journal of Endourology|2011|818
Intermittent versus Continuous Androgen Deprivation in Prostate Cancer
|New England Journal of Medicine|2013|568